Direct Vascular Effects of Angiotensin II (A Systematic Short Review)
Open Access
- 26 December 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 113
Abstract
The octapeptide angiotensin II (Ang II) is a circulating hormone as well as a locally formed agonist synthesized by the angiotensin-converting enzyme (ACE) of endothelial cells. It forms a powerful mechanism to control the amount and pressure of body fluids. All main effects are directed to save body salt and water and ensure blood pressure under basic conditions and in emergencies. All blood vessels respond to stimulation by Ang II; the immediate response is smooth muscle contraction, increasing vascular resistance, and elevating blood pressure. Such effects are conveyed by type 1 angiotensin receptors (AT1Rs) located in the plasma membrane of both endothelial and vascular smooth muscle cells. AT1Rs are heterotrimeric G protein-coupled receptors (GPCRs), but their signal pathways are much more complicated than other GPCRs. In addition to Gq/11, the G12/13, JAK/STAT, Jnk, MAPK, and ERK 1/2, and arrestin-dependent and -independent pathways are activated because of the promiscuous attachment of different signal proteins to the intracellular G protein binding site and to the intracellular C terminal loop. Substantial changes in protein expression follow, including the intracellular inflammation signal protein NF-κB, endothelial contact proteins, cytokines, matrix metalloproteinases (MMPs), and type I protocollagen, eliciting the inflammatory transformation of endothelial and vascular smooth muscle cells and fibrosis. Ang II is an important contributor to vascular pathologies in hypertensive, atherosclerotic, and aneurysmal vascular wall remodeling. Such direct vascular effects are reviewed. In addition to reducing blood pressure, AT1R antagonists and ACE inhibitors have a beneficial effect on the vascular wall by inhibiting pathological wall remodeling.Keywords
Funding Information
- Hungarian National Science Foundation (TO-32019, NK-72661, NK-100883, K-116954, K139231, 4.2.1.B-09/1/KMR-2010-0001, NVKP_16-1-2016-0039, VEKOP-2.3.2-16-2016-00002)
- The Hungarian Society of Hypertension Research Grant 2023 (M.S.) (TO-32019, NK-72661, NK-100883, K-116954, K139231, 4.2.1.B-09/1/KMR-2010-0001, NVKP_16-1-2016-0039, VEKOP-2.3.2-16-2016-00002)
- The Hungarian Kidney Foundation (TO-32019, NK-72661, NK-100883, K-116954, K139231, 4.2.1.B-09/1/KMR-2010-0001, NVKP_16-1-2016-0039, VEKOP-2.3.2-16-2016-00002)
- National Development Agency, Hungary TÁMOP (TO-32019, NK-72661, NK-100883, K-116954, K139231, 4.2.1.B-09/1/KMR-2010-0001, NVKP_16-1-2016-0039, VEKOP-2.3.2-16-2016-00002)
- Hungarian National Research, Development and Innovation (TO-32019, NK-72661, NK-100883, K-116954, K139231, 4.2.1.B-09/1/KMR-2010-0001, NVKP_16-1-2016-0039, VEKOP-2.3.2-16-2016-00002)
This publication has 160 references indexed in Scilit:
- Flexible and multifaceted: the plasticity of renin-expressing cellsPflügers Archiv - European Journal of Physiology, 2022
- The aging venous system: from varicosities to vascular cognitive impairmentGeroScience, 2021
- The pathophysiological role of angiotensin receptor-binding protein in hypertension and kidney diseases: Oshima Award Address 2019Clinical and Experimental Nephrology, 2020
- Endothelial cells expressing low levels of CD143 (ACE) exhibit enhanced sprouting and potency in relieving tissue ischemiaAngiogenesis, 2014
- Pulsatile Mechanical Pressure Promotes Angiotensin-Converting Enzyme Expression in Aortic Smooth Muscle CellsCardiovascular Drugs and Therapy, 2008
- Angiotensin‐converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesionsThe Journal of Pathology, 2008
- Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive dosesEuropean Journal of Clinical Pharmacology, 2006
- Endothelium-independent conversion of angiotensin I by vascular smooth muscle cellsCell and tissue research, 2001
- The Genomic Organization of Human Angiotensin II Type 1 ReceptorBiochemical and Biophysical Research Communications, 1994
- The conversion of angiotensin I to angiotensin II in vivoNaunyn-Schmiedeberg's Archives of Pharmacology, 1968